Information about Geographic Areas

9 Months Ended

Sep. 30, 2019

The Company operates as a single reportable segment and enables customers to perform both research and clinical testing on its nCounter Analysis and GeoMx DSP Systems. The Company has one sales force that sells these systems to both research and clinical testing labs, and certain of its nCounter reagents can be used for both research and diagnostic testing. GeoMx DSP reagents are sold for research use only. In addition, the Company’s Prosigna Breast Cancer Assay is marketed to clinical laboratories.

The following table of total revenue is based on the geographic location of distributors or end users who purchase products and services and collaborators. For sales to distributors, their geographic location may be different from the geographic locations of the ultimate end user. For collaboration agreements, revenues are derived from partners located primarily in the United States. Americas consists of the United States, Canada, Mexico and South America; and Asia Pacific includes Japan, China, South Korea, Singapore, Malaysia, India and Australia.

Revenue by geography was as follows (in thousands):



	Three Months Ended September 30,				Nine Months Ended September 30,
	2019		2018		2019		2018
Americas	$	21,730	$	21,032	$	63,235	$	53,865
Europe & Middle East	7,128		6,110		20,636		18,260
Asia Pacific	1,746		1,474		4,766		4,575
Total revenue	$	30,604	$	28,616	$	88,637	$	76,700

Total revenue in the United States was $21.3 million and $20.4 million for the three months ended September 30, 2019 and 2018, respectively, and $61.7 million and $51.2 million for the nine months ended September 30, 2019 and 2018, respectively. The Company’s assets are primarily located in the United States and not allocated to any specific geographic region. Substantially all of the Company’s long-lived assets are located in the United States.